[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339602-105":59,"doc-detail-339602-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunogenicity-of-non-mutated-ovarian-cancer-specific-antigens","Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens","","Epithelial ovarian cancer has not substantially benefited from immunotherapy due to insufficient actionable antigen targets. Proteogenomic analyses previously revealed 91 aberrantly expressed tumor-specific antigens arising from unmutated genomic sequences, driven by cancer-specific epigenetic changes. This study evaluates immunogenicity of 48 selected TSAs based on frequent HLA presentation and expression across a significant fraction of EOC tumors, using targeted mass spectrometry and T cell expansion assays.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunogenicity-of-non-mutated-ovarian-cancer-specific-antigens/339602/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunogenicity-of-non-mutated-ovarian-cancer-specific-antigens/339602.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy less effective in epithelial ovarian cancer?","Question",{"text":112,"@type":113},"Immunotherapy has shown limited benefit mainly because well-defined actionable antigen targets are lacking for effective T cell responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the tumor-specific antigens selected for this study?",{"text":117,"@type":113},"The study selected 48 TSAs based on two criteria: presentation by highly prevalent HLA allotypes and expression in a significant fraction of EOC tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental methods were used to assess immunogenicity?",{"text":121,"@type":113},"Targeted mass spectrometry assessed antigen presentation, and naïve CD8 T cell expansion was evaluated using MHC-peptide tetramer staining and TCR Vβ CDR3 sequencing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339602,1790040049,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Article  \nImmunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens  \nLeslie Hesnard 1, Catherine Thériault 1, Maxime Cahuzac 1, Chantal Durette 1, Krystel Vincent 1, Marie-Pierre Hardy 1, Joël Lanoix 1, Gabriel Ouellet Lavallée 1, Juliette Humeau 1, Pierre Thibault 1,2 and Claude Perreault 1,3, *  \nCitation: Hesnard, L.; Thériault, C.; Cahuzac, M.; Durette, C.; Vincent, K.; Hardy, M.-P.; Lanoix, J.; Lavallée, G.O.; Humeau, J.; Thibault, P.; et al. Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens. Curr. Oncol. 2024, 31, 3099–3121 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31060236  \nReceived: 4 April 2024  \nRevised: 24 May 2024  \nAccepted: 27 May 2024  \nPublished: 30 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; [leslie.hesnard@umontreal.ca](leslie.hesnard@umontreal.ca) (L.H.);  \ncatherine.theriault.4@umontreal.ca (C.T.); maxime.cahuzac@umontreal.ca (M.C.);  \n[chantal.durette@umontreal.ca](chantal.durette@umontreal.ca) (C.D.); [krystel.vincent@umontreal.ca](krystel.vincent@umontreal.ca) (K.V.);  \n[marie-pierre.hardy@umontreal.ca](marie-pierre.hardy@umontreal.ca) (M.-P.H.); [joel.lanoix@umontreal.ca](joel.lanoix@umontreal.ca) (J.L.);  \n[gabriel.ouellet.lavallee@umontreal.ca](gabriel.ouellet.lavallee@umontreal.ca) (G.O.L.); [juliette.f.humeau@gmail.com](juliette.f.humeau@gmail.com) (J.H.);  \n[pierre.thibault@umontreal.ca](pierre.thibault@umontreal.ca) (P.T.)  \n2 Department of Chemistry, University of Montreal, Montreal, QC H2V 0B3, Canada  \n3 Department of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada  \n* Correspondence: [claude.perreault@umontreal.ca](claude.perreault@umontreal.ca)  \nAbstract: Epithelial ovarian cancer (EOC) has not significantly benefited from advances in immunotherapy, mainly because of the lack of well-defined actionable antigen targets. Using proteogenomic analyses of primary EOC tumors, we previously identified 91 aberrantly expressed tumor-specific antigens (TSAs) originating from unmutated genomic sequences. Most of these TSAs derive from non-exonic regions, and their expression results from cancer-specific epigenetic changes. The present study aimed to evaluate the immunogenicity of 48 TSAs selected according to two criteria: presentation by highly prevalent HLA allotypes and expression in a significant fraction of EOC tumors. Using targeted mass spectrometry analyses, we found that pulsing with synthetic TSA peptides leads to a high-level presentation on dendritic cells. TSA abundance correlated with the predicted binding affinity to the HLA allotype. We stimulated naïve CD8 T cells from healthy blood donors with TSA-pulsed dendritic cells and assessed their expansion with two assays: MHC-peptide tetramer staining and TCR Vβ CDR3 sequencing. We report that these TSAs can expand sizeable populations of CD8 T cells and, therefore, represent attractive targets for EOC immunotherapy.  \nKeywords: tumor-specific antigen; vaccine; mass spectrometry; antigen presentation; immunogenicity; dendritic cells  \n1. Introduction  \nEpithelial ovarian cancer (EOC) is the leading cause of gynecological cancer death. High-grade serous ovarian carcinoma represents 70% of EOC and accounts for 90% of advanced-stage disease and mortality [1,2] . The late diagnosis is one of the main factors contributing to a low 5-year survival rate recently estimated at 50%[3] . EOC is considered a tumor type with potential immunoreactivity due to the well-documented positive correlation between the presence of tumor-infiltrating","cbCaiqap3NbJ3MQU","https://ap.wps.com/l/cbCaiqap3NbJ3MQU","pdf",3663226,23,"English","# Abstract\n# Introduction","[{\"question\":\"Why is immunotherapy less effective in epithelial ovarian cancer?\",\"answer\":\"Immunotherapy has shown limited benefit mainly because well-defined actionable antigen targets are lacking for effective T cell responses.\"},{\"question\":\"How were the tumor-specific antigens selected for this study?\",\"answer\":\"The study selected 48 TSAs based on two criteria: presentation by highly prevalent HLA allotypes and expression in a significant fraction of EOC tumors.\"},{\"question\":\"What experimental methods were used to assess immunogenicity?\",\"answer\":\"Targeted mass spectrometry assessed antigen presentation, and naïve CD8 T cell expansion was evaluated using MHC-peptide tetramer staining and TCR Vβ CDR3 sequencing.\"}]","Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens | PDF",1790031191,58]